你的浏览器似乎禁用了 JavaScript。
您必须在浏览器中启用JavaScript才能使用本网站的功能。

微信关注
申请试用装

主页 /
Epigenetics

Epigenetics

Quick View
WP1066

Catalog No. A11795
Quick View

添加到收藏
JAK 抑制剂

WP1066是一种新型的JAK2抑制剂，可抑制携带JAK2 V617F突变的类人甲状腺细胞增殖并诱导其凋亡。了解更多

Product Citations (1)

Bulk Inquiry Free Sample
- Simona Moravcova, .et al. The Circadian Rhythms of STAT3 in the Rat Pineal Gland and Its Involvement in Arylalkylamine-N-Acetyltransferase Regulation, Life (Basel), 2021, Oct 18;11(10):1105 PMID: 34685476
Quick View
BMS-911543

Catalog No. A11241
Quick View

添加到收藏
JAK 抑制剂

BMS-911543是一种有效的、选择性JAK2小分子抑制剂。了解更多

Bulk Inquiry Free Sample
Quick View
Go 6976

Catalog No. A12419
添加到收藏
PKC 抑制剂

Go6976是一种有效的PKC抑制剂，对PKC（大鼠脑），PKCα和PKCβ1的IC50分别为7.9 nM，2.3 nM和6.2 nM。也是JAK2和Flt3的有效抑制剂。了解更多

Bulk Inquiry
Quick View
Pacritinib (SB1518)

Catalog No. A12694
Quick View

添加到收藏
JAK2/FLT3 抑制剂

Pacritinib (SB1518)是Janus激酶2（JAK2）和JAK2突变体JAK2V617F的口服生物利用抑制剂，无细胞试验中IC50分别为23和22 nM，具有潜在的抗肿瘤活性。Pacritinib与JAK2竞争ATP结合，这可能导致抑制JAK2活化，抑制JAK-STAT信号传导途径以及半胱天冬酶依赖性凋亡。了解更多

Product Citations (1)

Bulk Inquiry Free Sample
- Daniel Doheny, .et al. Combined inhibition of JAK2-STAT3 and SMO-GLI1/tGLI1 pathways suppresses breast cancer stem cells, tumor growth, and metastasis, Oncogene, 2020, Oct;39(42):6589-6605 PMID: 32929154
Quick View
CEP33779

Catalog No. A12808
Quick View

添加到收藏
JAK2 抑制剂

CEP33779是选择性JAK2抑制剂，IC50为1.8 nM。了解更多

Bulk Inquiry Free Sample
Quick View
XL019

Catalog No. A12394
Quick View

添加到收藏
JAK2 抑制剂

XL019是janus相关激酶2 (JAK-2)的生物可利用抑制剂，具有潜在的抗肿瘤活性。了解更多

Bulk Inquiry Free Sample
Quick View
PF-03394197 (oclacitinib)

Catalog No. A13082
Quick View

添加到收藏
JAK1 抑制剂

PF-03394197 (oclacitinib)是有效的JAK1抑制剂。了解更多

Product Citations (3)

Bulk Inquiry
- Banovic F, .et al. Immunomodulatory in vitro effects of oclacitinib on canine T-cell proliferation and cytokine production, Vet Dermatol, 2018, Nov 12 PMID: 30417482
- Nicholas B, .et al. Susceptibility to influenza virus infection of bronchial biopsies in asthma, J Allergy Clin Immunol, 2017, Jul;140(1):309-312.e4 PMID: 28259448
- Fukuyama T, .et al. Topically Administered Janus-Kinase Inhibitors Tofacitinib and Oclacitinib Display Impressive Antipruritic and Anti-Inflammatory Responses in a Model of Allergic Dermatitis., J Pharmacol Exp Ther., 2015, Sep;354(3):394-405 PMID: 26159873
Quick View
GLPG0634

Catalog No. A13162
Quick View

添加到收藏
JAK1 抑制剂

GLPG0634是一种口服的JAK1(Janus激酶1)选择性抑制剂，对 JAK1/JAK2/JAK3的IC50值为50-200 nM。用于治疗类风湿性关节炎和潜在的其他炎性疾病。了解更多

Product Citations (1)

Bulk Inquiry Free Sample
- Keisuke Nishimura, .et al. Tofacitinib facilitates the expansion of myeloid-derived suppressor cells and ameliorates arthritis in SKG mice., Arthritis Rheumatol., 2015, Apr;67(4):893-902 PMID: 25545152
Quick View
Pyridone 6 (JAK Inhibitor I)

Catalog No. A13457
Quick View

添加到收藏
JAK 抑制剂

JAK Inhibitor I 是JAK1、JAK2和JAK3的一种高效、可逆、细胞通透性和ATP竞争性抑制剂。了解更多

Bulk Inquiry Free Sample
Quick View
WHI-P 154

Catalog No. A14049
Quick View

添加到收藏
JAK3 抑制剂

WHI-P 154是一种JAK3抑制剂，IC50 = 1.8uM。WHI-P 154还在体外抑制巨噬细胞中的STAT1激活，iNOS表达和NO生成。了解更多

Bulk Inquiry
Quick View
PRT 062070 (Cerdulatinib)

Catalog No. A14147
Quick View

添加到收藏
Dual Syk and JAK 抑制剂

PRT 062070 (Cerdulatinib)是一种新型的口服双脾酪氨酸激酶（Syk）和janus激酶（JAK）抑制剂。Cerdulatinib优先抑制各种细胞类型中JAK1和JAK3依赖性细胞因子介导的信号传导和功能性反应。了解更多

Bulk Inquiry
Quick View
NSC 42834(JAK2 Inhibitor V, Z3)

Catalog No. A14132
Quick View

添加到收藏
JAK2 抑制剂

NSC 42834(JAK2 Inhibitor V,Z3)是一种新型的Jak2酪氨酸激酶特异性抑制剂。了解更多

Bulk Inquiry
Quick View
Cerdulatinib

Catalog No. A14210
Quick View

添加到收藏
multi-targeted tyrosine kinase 抑制剂

Cerdulatinib (PRT-062070)是多靶点酪氨酸激酶抑制剂，对JAK1/JAK2/JAK3/TYK2和Syk的IC50分别为12 nM/6 nM/8 nM/0.5 nM和32 nM。了解更多

Bulk Inquiry Free Sample
Quick View
Filgotinib

Catalog No. A14232
Quick View

添加到收藏
JAK 抑制剂

Filgotinib是一种选择性的JAK1抑制剂，对于JAK1，JAK2，JAK3和TYK2的IC50分别为10 nM，28 nM，810 nM和116 nM。了解更多

Bulk Inquiry Free Sample
Quick View
INCB39110 (Itacitinib)

Catalog No. A14390
Quick View

添加到收藏
JAK1 抑制剂

INCB39110 (Itacitinib)是一种有效的JAK1酪氨酸激酶抑制剂，目前正在II期试验中，用于治疗类风湿关节炎，骨髓纤维化，类风湿关节炎和斑块状牛皮癣。了解更多

Product Citations (1)

Bulk Inquiry
- Czech J, .et al. JAK2V617F but not CALR mutations confer increased molecular responses to interferon-α via JAK1/STAT1 activation, Leukemia, 2018, Nov 23 PMID: 30470838
Quick View
Solcitinib (GSK2586184)

Catalog No. A14405
Quick View

添加到收藏
JAK1 抑制剂

Solcitinib (GSK2586184)是Janus激酶1（JAK1）抑制剂。了解更多

Bulk Inquiry
Quick View
Decernotinib

Catalog No. A14012
Quick View

添加到收藏
JAK3 抑制剂

Decernotinib是Vertex开发的口服选择性Janus激酶3（JAK3）抑制剂。了解更多

Bulk Inquiry
Quick View
ZM 39923 HCl

Catalog No. A13509
Quick View

添加到收藏
JAK3 抑制剂

ZM 39923 HCl是JAK3抑制剂（IC50 = 79 nM），其抑制表皮生长因子受体，JAK1和细胞周期蛋白依赖性激酶4（IC50s分别为2.4、40和10 M）的抑制作用较小。了解更多

Bulk Inquiry
Quick View
S-Ruxolitinib

Catalog No. A14955
Quick View

添加到收藏
JAK 抑制剂

S-Ruxolitinib是INCB018424的手性化合物，是一种有效且选择性的小分子Janus激酶1（JAK1）和JAK2抑制剂。了解更多

Bulk Inquiry
Quick View
CYT387 sulfate salt

Catalog No. A15056
Quick View

添加到收藏
JAK 抑制剂

CYT387 sulfate salt是JAK1/JAK2的ATP竞争性抑制剂，IC50为11 nM/18 nM，是JAK3的约10倍选择性。了解更多

Bulk Inquiry
Quick View
JANEX-1

Catalog No. A15134
Quick View

添加到收藏
JAK3 抑制剂

Janex-1是JAK3的细胞渗透性，可逆性，有效，ATP竞争性和特异性抑制剂（IC50 = 78 uM）；对JAK1，JAK2或Zap/Syk或SRC酪氨酸激酶无影响。了解更多

Bulk Inquiry Free Sample
Quick View
1,2,3,4,5,6-Hexabromocyclohexane

Catalog No. A15361
Quick View

添加到收藏
JAK2 抑制剂

1,2,3,4,5,6-Hexabromocyclohexane是一种有效且特异性的JAK2自磷酸化抑制剂。了解更多

Bulk Inquiry
Quick View
Cercosporamide

Catalog No. A15362
添加到收藏
Mnk2/JAK3 抑制剂

Cercosporamide是一种USnic酰胺，最初在Cercosporidium henningsii中被鉴定为宿主选择性植物毒素和广谱抗真菌剂，并且是MAP激酶相互作用激酶2（Mnk2；IC50 = 11 nM），JAK3（IC50 = 31）和Mnk1（IC50 = 116 nM）。了解更多

Bulk Inquiry
Quick View
Cucurbitacin I

Catalog No. A15363
添加到收藏
JAK2/STAT3 抑制剂

Cucurbitacin I（Cucumis sativus L.）可以抑制v-Src转化的NIH 3T3细胞中的磷酸酪氨酸Stat3（信号转导和转录激活因子3）水平。了解更多

Bulk Inquiry
Quick View
SD 1008

Catalog No. A15364
Quick View

添加到收藏
JAK2/STAT3 抑制剂

SD 1008是JAK2/STAT3信号通路抑制剂，可额外抑制Src。注意到SD 1008可诱导表达组成性活性酪氨酸磷酸化STAT3的细胞系凋亡。了解更多

Bulk Inquiry
Quick View
TCS 21311

Catalog No. A15365
Quick View

添加到收藏
JAK3 抑制剂

TCS 21311是有效的JAK3抑制剂（IC50 = 8 nM）。TCS 21311对于JAK3相对于JAK1，JAK2和Tyk 2具有选择性（IC50值分别为1017、2550和8055 nM）。了解更多

Bulk Inquiry
Quick View
ZM 449829

Catalog No. A15366
Quick View

添加到收藏
JAK/STAT 抑制剂

ZM 449829是有效的、选择性的JAK3抑制剂（Janus酪氨酸激酶3），与JAK3 ATP位点竞争性结合。了解更多

Bulk Inquiry
Quick View
NSC 33994

Catalog No. A15389
Quick View

添加到收藏
JAK2 抑制剂

NSC 33994是JAK2酪氨酸激酶（Janus激酶2）的新型抑制剂。Janus激酶2（JAK2）在骨髓增生性疾病和血液系统恶性肿瘤的发病机制中起着至关重要的作用。了解更多

Bulk Inquiry
Quick View
Baricitinib phosphate

Catalog No. A15014
Quick View

添加到收藏
JAK 抑制剂

Baricitinib phosphate是一种选择性的JAK1和JAK2抑制剂，IC50为5.9 nM和5.7 nM，选择性是JAK3和Tyk2的?70和?10倍，对c-Met和Chk2没有抑制作用。了解更多

Bulk Inquiry
Quick View
Peficitinib (ASP015K, JNJ-54781532)

Catalog No. A14438
Quick View

添加到收藏
JAK 抑制剂?

Peficitinib (ASP015K,JNJ-54781532)是一种新型的强力JAK抑制剂，在佐剂诱导的大鼠关节炎模型中显示出强效功效。了解更多

Bulk Inquiry
Quick View
FLLL32

Catalog No. A15911
Quick View

添加到收藏
JAK2 抑制剂

FLLL32是一种有效的JAK2/STAT3双重抑制剂，IC50 <5 uM。了解更多

Bulk Inquiry
Quick View
WHI-P97

Catalog No. A11608
Quick View

添加到收藏
JAK3 抑制剂

WHI-P97是合理设计的JAK-3抑制剂。了解更多

Bulk Inquiry
Quick View
NS-018

Catalog No. A16224
Quick View

添加到收藏
JAK2 抑制剂

NS-018是Janus相关激酶2（JAK2）和Src家族激酶的口服生物利用型小分子抑制剂，具有潜在的抗肿瘤活性。了解更多

Bulk Inquiry
Quick View
NS-018 hydrochloride

Catalog No. A16225
Quick View

添加到收藏
JAK2 抑制剂

NS-018 hydrochloride是一种新型的高选择性JAK2抑制剂。了解更多

Bulk Inquiry
Quick View
NS-018 maleate

Catalog No. A16226
Quick View

添加到收藏
JAK2 抑制剂

NS-018 maleate是在Ba/F3-JAK2V617F细胞中具有ATP竞争性的JAK2小分子抑制剂，IC50为470nM。与其他JAK家族激酶（例如JAK1，JAK3和酪氨酸激酶2）相比，对JAK2的选择性高30-50倍。了解更多

Bulk Inquiry
Quick View
ZM39923

Catalog No. A16227
Quick View

添加到收藏
JAK1/3 抑制剂

ZM39923是一种JAK1/3抑制剂，pIC50为4.4/7.1，对JAK2几乎没有活性，对EGFR的作用中等。还发现对转谷氨酰胺酶敏感。了解更多

Bulk Inquiry
Quick View
AZ-3

Catalog No. A19217
Quick View

添加到收藏
JAK1 inhibitor

AZ-3 is a potent and selective JAK1 inhibitor with an IC50 of 34 nM. 了解更多

Bulk Inquiry
Quick View
Delgocitinib

Catalog No. A19234
Quick View

添加到收藏
JAK inhibitor

Delgocitinib is a novel and specific JAK inhibitor with IC50s of 2.8, 2.6, 13 and 58 nM for JAK1, JAK2, JAK3 and Tyk2, respectively. 了解更多

Bulk Inquiry
Quick View
JAK1-IN-3

Catalog No. A19251
Quick View

添加到收藏
JAK1 inhibitor

JAK1-IN-3 is a selective JAK1 inhibitor, with an IC50 of 73 nM, weakly inhibits JAK2, and shows little inhibition on JAK3 (IC50, >14.7, >30 μM, respectively). 了解更多

Bulk Inquiry
Quick View
JAK-IN-5

Catalog No. A19792
Quick View

添加到收藏
JAK inhibitor

JAK-IN-5 is an inhibitor of JAK extracted from patent US20170121327A1, compound example 283. 了解更多

Bulk Inquiry
Quick View
Gusacitinib

Catalog No. A19883
Quick View

添加到收藏
SYK/JAK inhibitor

Gusacitinib (ASN-002) is a potent dual inhibitor of spleen tyrosine kinase (SYK) and janus kinase (JAK) with IC50 values of 5-46 nM. 了解更多

Bulk Inquiry
Quick View
JAK-IN-3

Catalog No. A20220
Quick View

添加到收藏
JAK inhibitor

JAK-IN-3 (compound 22) is a potent JAK inhibitor, with IC50 values of 3 nM, 5 nM, 34 nM and 70 nM for JAK3, JAK1, TYK2 and JAK2, respectively. 了解更多

Bulk Inquiry
Quick View
JAK-IN-4

Catalog No. A20230
Quick View

添加到收藏
JAK inhibitor

JAK-IN-4 is a prodrug of a JAK inhibitor, effective in murine collagen induced arthritis model. 了解更多

Bulk Inquiry
Quick View
SAR-20347

Catalog No. A20380
Quick View

添加到收藏
TYK2/JAK1/JAK2/JAK3 inhibitor

SAR-20347 is an inhibitor of TYK2, JAK1, JAK2 and JAK3 with IC50s of 0.6, 23, 26 and 41 nM, respectively. 了解更多

Bulk Inquiry
Quick View
JAK3-IN-1

Catalog No. A20734
Quick View

添加到收藏
JAK3 inhibitor

JAK3-IN-1 is a potent JAK3 inhibitor with IC50 of 4.8 nM, also inhibits JAK1 (IC50 = 896 nM) and JAK2 (IC50 = 1050 nM). 了解更多

Bulk Inquiry
Quick View
ABT-888 (Veliparib)

Catalog No. A10026
Quick View

添加到收藏
PARP 抑制剂

ABT-888 (Veliparib)是一种潜在的抗癌药物，可作为PARP抑制剂。了解更多

Product Citations (1)

Bulk Inquiry Free Sample
- Subhajit Chatterjee, .et al. PARP inhibitor Veliparib (ABT-888) enhances the anti-angiogenic potentiality of Curcumin through deregulation of NECTIN-4 in oral cancer: Role of nitric oxide (NO), Cell Signal, 2021, Apr;80:109902 PMID: 33373686
Quick View
Olaparib (AZD2281)

Catalog No. A10111
Quick View

添加到收藏
PARP 抑制剂

Olaparib (AZD2281)是聚ADP核糖聚合酶（PARP）的抑制剂，该酶是一种与DNA修复有关的酶。了解更多

Product Citations (28)

Bulk Inquiry Free Sample
- Saptarshi Sinha, .et al. Olaparib enhances the Resveratrol-mediated apoptosis in breast cancer cells by inhibiting the homologous recombination repair pathway, Exp Cell Res, 2022, Nov 1;420(1):113338 PMID: 36075449
- Subhajit Chatterjee, .et al. Combination of talazoparib and olaparib enhanced the curcumin-mediated apoptosis in oral cancer cells by PARP-1 trapping, J Cancer Res Clin Oncol, 2022, Dec;148(12):3521-3535 PMID: 35962813
- Yuki Uchihara, .et al. DNA damage promotes HLA class I presentation by stimulating a pioneer round of translation-associated antigen production, Mol Cell, 2022, Jul 21;82(14):2557-2570 PMID: 35594857
- Ji-Ye Kim, .et al. ARL6IP5 reduces cisplatin-resistance by suppressing DNA repair and promoting apoptosis pathways in ovarian carcinoma, Cell Death Dis, 2022, Mar 15;13(3):239 PMID: 35293383
- Emad Matanes, .et al. Inhibition of Poly ADP-Ribose Glycohydrolase Sensitizes Ovarian Cancer Cells to Poly ADP-Ribose Polymerase Inhibitors and Platinum Agents, Front Oncol, 2021, Oct 27;11:745981 PMID: 34778062
- Shino Endo, .et al. BRCA1/ATF1-Mediated Transactivation is Involved in Resistance to PARP Inhibitors and Cisplatin, Cancer Res Commun, 2021, 1(2): 90-105
- Yan Baglo, .et al. Evolutionary dynamics of cancer multidrug resistance in response to olaparib and photodynamic therapy, Transl Oncol, 2021, Nov;14(11):101198 PMID: 34418731
- Joseph M Gozgit, .et al. PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity, Cancer cell, 2021, Jul 22;S1535-6108(21)00340-8 PMID: 34375612
- Sefinew Molla, .et al. Olaparib enhances curcumin-mediated apoptosis in oral cancer cells by inducing PARP trapping through modulation of BER and chromatin assembly, DNA Repair (Amst), 2021, Jun 10;105:103157 PMID: 34144488
- Jianming Wang, .et al. Persistence of RNA transcription during DNA replication delays duplication of transcription start sites until G2/M, Cell Rep, 2021, Feb 16;34(7):108759 PMID: 33596418
- Ai Ito, .et al. Metolazone upregulates mitochondrial chaperones and extends lifespan in Caenorhabditis elegans, Biogerontology, 2021, Feb;22(1):119-131 PMID: 33216250
- Tim J Wigle, .et al. In Vitro and Cellular Probes to Study PARP Enzyme Target Engagement, Cell Chem Biol, 2020, Jul 16;27(7):877-887 PMID: 32679093
- Ali Divan, .et al. Structurally unique PARP-1 inhibitors for the treatment of prostate cancer, Pharmacol Res Perspect, 2020, Apr; 8(2): e00586 PMID: 32342655
- Jianwei Dou, .et al. Development and evaluation of poly adenosine 5'-diphosphate-ribose polymerase 1 immobilization-based receptor chromatography, J Sep Sci, 2020, Dec 4 PMID: 33275824
- Sai Dimple Manavitha Gullipalli, .et al. Development and Validation of Bioanalytical Method for Estimation of Niraparib in Rat Plasma Using High Performance LC-MS/MS And Its Application to Pharmacokinetic Study, Int. J. Adv. Pharm. Biotech, 2020, 6(2) 01-08
- Chao Zhang, .et al. Phenotypic Switching of Atherosclerotic Smooth Muscle Cells is Regulated by Activated PARP1-Dependent TET1 Expression, J Atheroscler Thromb, 2020, Sep 25 PMID: 32981917
- Wigle TJ, .et al. Forced Self-Modification Assays as a Strategy to Screen MonoPARP Enzymes, SLAS Discov, 2019, Dec 19:2472555219883623 PMID: 31855104
- Wang Q, .et al. Biguanides in combination with olaparib limits tumorigenesis of drug-resistant ovarian cancer cells through inhibition of Snail, Cancer Med, 2019, Dec 21 PMID: 31863638
- Molla S, .et al. PARP inhibitor Olaparib Enhances the Apoptotic Potentiality of Curcumin by Increasing the DNA Damage in Oral Cancer Cells through Inhibition of BER Cascade, Pathol Oncol Res, 2019, Nov 25 PMID: 31768967
- Alvin Z.Lu, .et al. Enabling drug discovery for the PARP protein family through the detection of mono-ADP-ribosylation, Biochem Pharmacol, 2019, May 7. pii: S0006-2952(19)30171-6 PMID: 31075269
- Bian C, .et al. NADP+ is an endogenous PARP inhibitor in DNA damage response and tumor suppression, Nat Commun, 2019, Feb 11;10(1):693 PMID: 30741937
- HC de Silva, .et al. IGFBP-3 interacts with NONO and SFPQ in PARP-dependent DNA damage repair in triple-negative breast cancer, Cell Mol Life Sci, 2019, 1-16 PMID: 30725116
- Kamada Y, .et al. Castalagin and vescalagin purified from leaves of Syzygium samarangense (Blume) Merrill & L.M. Perry: Dual inhibitory activity against PARP1 and DNA topoisomerase II, Fitoterapia, 2018, Sep;129:94-101 PMID: 29928967
- 2018, .et al. Augmentation of the therapeutic efficacy of WEE1 kinase inhibitor AZD1775 by inhibiting the YAP-E2F1-DNA damage response pathway axis, FEBS Open Bio, 2018, Jun; 8(6): 1001-1012 PMID: 29928579
- Hirosumi Tamura, .et al. Evaluation of anticancer agents using patient-derived tumor organoids characteristically similar to source tissues, Oncol Rep, 2018, Aug; 40(2): 635-646 PMID: 29917168
- Hiro Sato, .et al. DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells, Nat Commun, 2017, 8: 1751 PMID: 29170499
- Charles-André Philip, .et al. Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors, BMC Cancer, 2017, 17: 638 PMID: 28886696
- Rulina AV, .et al. Distinct outcomes of CRL-Nedd8 pathway inhibition reveal cancer cell plasticity, Cell Death Dis, 2016, Dec 1;7(12):e2505 PMID: 27906189
Quick View
BSI-201 (Iniparib)

Catalog No. A10164
Quick View

添加到收藏
PARP 抑制剂

BSI-201 (Iniparib)是一种有效的PARP-1抑制剂，已被证明可以穿越血脑屏障。了解更多

Product Citations (1)

Bulk Inquiry Free Sample
- Jianwei Dou, .et al. Development and evaluation of poly adenosine 5'-diphosphate-ribose polymerase 1 immobilization-based receptor chromatography, J Sep Sci, 2020, Dec 4 PMID: 33275824
Quick View
AG-014699 (Rucaparib)

Catalog No. A10045
Quick View

添加到收藏
PARP 抑制剂

AG-014699 (Rucaparib)是一种PARP抑制剂，可抑制聚（ADP-核糖）聚合酶（PARP，后者是DNA修复中的关键酶。无细胞试验中作用于PARP1的Ki为1.4 nM，对其余8个PARP位点也有结合亲和力。了解更多

Product Citations (1)

Bulk Inquiry
- Tahira Baloch, .et al. Sequential therapeutic targeting of ovarian Cancer harboring dysfunctional BRCA1, BMC Cancer, 2019, Jan 10;19(1):44 PMID: 30630446
Quick View
AG14361

Catalog No. A10046
Quick View

添加到收藏
PARP 抑制剂

AG14361是一种有效的PARP抑制剂，可在MMR（错配修复）有效/不足的细胞中增强替莫唑胺（TMZ）的细胞毒性。了解更多

Product Citations (1)

Bulk Inquiry Free Sample
- Vimal Pandey, .et al. Roscovitine effectively enhances antitumor activity of temozolomide in vitro and in vivo mediated by increased autophagy and Caspase-3 dependent apoptosis, Scientific Reports, 2019, 9, Article number: 5012

联系我们

Not your Region? View all Distributors

溶液配制计算器

分子量计算器

稀释计算器

摩尔浓度计算器

ADOOQ 产品质量保证

Guaranteed product quality, 365 days Unconditional Return & Replacement

We promise all products to perform as described.